Physician profile
Todd Rozycki
NPI 1407846967
$5,550.65
in general payments reported to CMS, 2019-2025
35 companies · $1,702 in 2025
The $1,702 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $300 · 2021: $313 · 2022: $527 · 2023: $1,395 · 2024: $1,001 · 2025: $1,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,969 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,969.36 |
| Education | $127.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $680.71 | 2019-2025 | Tremfya |
| Amgen INC. | $651.69 | 2020-2025 | Otezla, Otezla |
| Abbvie INC. | $434.83 | 2020-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $398.98 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $341.86 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $295.40 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $275.76 | 2020-2024 | Blu-U, Odomzo, Ilumya |
| Ucb, INC. | $238.00 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $203.48 | 2024-2025 | |
| Strata Skin Sciences, INC. | $196.27 | 2020-2023 | Xtrac |
| Dermavant Sciences, INC. | $182.98 | 2022-2024 | Vtama |
| Genzyme Corporation | $160.85 | 2021-2025 | |
| Lilly USA, LLC | $157.85 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Convatec INC. | $141.94 | 2025 | |
| Leo Pharma INC. | $138.71 | 2022-2025 | Adbry |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $113.23 | 2024-2025 | Collagenase Santyl |
| Stemline Therapeutics INC. | $108.01 | 2019-2022 | |
| Genentech USA, INC. | $102.65 | 2023-2025 | Xolair |
| Janssen Scientific Affairs, LLC | $100.00 | 2019 | |
| Fresenius Kabi USA, LLC | $84.35 | 2023-2024 | Idacio |
| Pfizer INC. | $68.82 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $68.74 | 2024-2025 | Acthar |
| Almirall LLC | $68.01 | 2019-2023 | Klisyri |
| Organogenesis INC. | $67.08 | 2023-2025 | Puraply, Via Matrix |
| Arcutis Biotherapeutics, INC. | $64.53 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $49.81 | 2020-2025 | Nemluvio |
| Surgenex LLC | $22.10 | 2025 | Ardeograft, Surmatrix, Pellograft |
| Vyne Pharmaceuticals INC. | $21.16 | 2020 | |
| Springworks Therapeutics, INC. | $19.51 | 2025 | Gomekli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.36 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.70 | 2025 | Ycanth |
| Dusa Pharmaceuticals, INC. | $15.53 | 2019 | |
| Journey Medical Corporation | $13.93 | 2025 | |
| Merck Sharp & Dohme LLC | $13.53 | 2022 | |
| Kerecis Limited | $12.29 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Rozycki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.